164 related articles for article (PubMed ID: 28246192)
1. More than 1
Montalban-Bravo G; Benton CB; Wang SA; Ravandi F; Kadia T; Cortes J; Daver N; Takahashi K; DiNardo C; Jabbour E; Borthakur G; Konopleva M; Pierce S; Bueso-Ramos C; Patel K; Kornblau S; Kantarjian H; Young KH; Garcia-Manero G; Andreeff M
Blood; 2017 May; 129(18):2584-2587. PubMed ID: 28246192
[No Abstract] [Full Text] [Related]
2. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.
Tashakori M; Wang W; Kadia TM; Daver NG; Montalban-Bravo G; Loghavi S; Wang SA; Medeiros LJ; Ravandi F; Khoury JD
Leuk Res; 2022 Jul; 118():106860. PubMed ID: 35636055
[TBL] [Abstract][Full Text] [Related]
3. Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification.
Cervera N; Carbuccia N; Mozziconacci MJ; Adélaïde J; Garnier S; Guille A; Murati A; Chaffanet M; Vey N; Birnbaum D; Gelsi-Boyer V
Blood Cancer J; 2017 Aug; 7(8):e594. PubMed ID: 28841205
[No Abstract] [Full Text] [Related]
4. Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing.
Cervera N; Carbuccia N; Garnier S; Guille A; Adélaïde J; Murati A; Vey N; Mozziconacci MJ; Chaffanet M; Birnbaum D; Gelsi-Boyer V
Leukemia; 2016 Apr; 30(4):966-70. PubMed ID: 26202927
[No Abstract] [Full Text] [Related]
5. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics.
Grossmann V; Bacher U; Haferlach C; Schnittger S; Pötzinger F; Weissmann S; Roller A; Eder C; Fasan A; Zenger M; Staller M; Kern W; Kohlmann A; Haferlach T
Leukemia; 2013 Sep; 27(9):1940-3. PubMed ID: 23648669
[No Abstract] [Full Text] [Related]
6. Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.
Salmoiraghi S; Montalvo ML; Ubiali G; Tosi M; Peruta B; Zanghi P; Oldani E; Boschini C; Kohlmann A; Bungaro S; Intermesoli T; Terruzzi E; Angelucci E; Cavattoni I; Ciceri F; Bassan R; Rambaldi A; Spinelli O
Haematologica; 2016 Jun; 101(6):e245-8. PubMed ID: 26992948
[No Abstract] [Full Text] [Related]
7. [The prognosis and cytogenetic characteristics of acute erythroid leukemia: a report of 55 cases].
Liu J; Lu DP; Zhang Y
Zhonghua Nei Ke Za Zhi; 2006 Sep; 45(9):738-40. PubMed ID: 17166448
[TBL] [Abstract][Full Text] [Related]
8. Acute leukaemia with a pure erythroid phenotype: under-recognized morphological and cytogenetic signatures associated universally with primary refractory disease and a dismal clinical outcome.
Park DC; Ozkaya N; Lovitch SB
Histopathology; 2017 Aug; 71(2):316-321. PubMed ID: 28261852
[TBL] [Abstract][Full Text] [Related]
9. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
[TBL] [Abstract][Full Text] [Related]
10. [Molecular pathogenesis and therapeutic targets in acute erythroid leukemia].
Takeda J
Rinsho Ketsueki; 2022; 63(2):121-133. PubMed ID: 35264503
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
Omura G; Ando M; Ebihara Y; Saito Y; Kobayashi K; Fukuoka O; Akashi K; Yoshida M; Asakage T; Yamasoba T
BMC Cancer; 2017 Dec; 17(1):898. PubMed ID: 29282038
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: a retrospective study of 54 cases.
Colita A; Belhabri A; Chelghoum Y; Charrin C; Fiere D; Thomas X
Ann Oncol; 2001 Apr; 12(4):451-5. PubMed ID: 11398875
[TBL] [Abstract][Full Text] [Related]
16. Deep targeted sequencing of
Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
[TBL] [Abstract][Full Text] [Related]
17. Pure erythroid leukemia with hemophagocytosis.
Kitagawa J; Hara T; Tsurumi H; Oyama M; Moriwaki H
Intern Med; 2009; 48(18):1695-8. PubMed ID: 19755777
[TBL] [Abstract][Full Text] [Related]
18. Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia.
Prasher JM; Elenitoba-Johnson KS; Kelley LL
Oncogene; 2001 May; 20(23):2946-55. PubMed ID: 11420707
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
20. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
Kobayashi K; Yoshimoto S; Matsumoto F; Ando M; Murakami N; Omura G; Fukasawa M; Matsumoto Y; Matsumura S; Akamatsu M; Hiraoka N; Eigitsu R; Mori T
Ann Surg Oncol; 2019 Jul; 26(7):2294-2303. PubMed ID: 30900104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
